Sareptatherapeutics.com
Visit sareptatherapeutics.comWe collected all of metadata history records for Sareptatherapeutics.com. Sarepta Therapeutics has an elaborated description which rather positively influences the efficiency of search engines index and hence improves positions of the domain. The description and keywords of Sareptatherapeutics were last changed more than 2 months ago.
Sareptatherapeutics.com metadata updates
| Title | Description | Keywords |
|---|---|---|
|
March 14, 2020 Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases |
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sar... |
|
|
October 11, 2019 Sarepta Therapeutics | Focused on precision genetic medicines to treat rare neuromuscular diseases |
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) an... |
Sarepta, Gene Therapy, micro-dystrophin, Limb-girdle muscular dystrophy diseases (LGMD), C... |
|
November 28, 2016 Sarepta Therapeutics | Focused on RNA-targeted therapeutics |
We are Sarepta Therapeutics: a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics. Our goal is to harness the power ... |
Sarepta, RNA therapeutics, Duchenne, Duchenne muscular dystrophy, DMD, exon skipping, etep... |
|
August 08, 2016 The Leader in RNA-targeted Medicine | Sarepta Therapeutics |
We develop RNA-based therapeutics to improve the lives of people affected by serious diseases; this includes eteplirsen for the treatment of DMD. |
Sarepta, RNA therapeutics, Duchenne muscular dystrophy, DMD, exon skipping, eteplirsen |
|
April 15, 2014 The Leader in RNA-based Medicine | Sarepta Therapeutics |
We develop RNA-based therapeutics to improve the lives of people affected by serious diseases; this includes eteplirsen for the treatment of DMD. |
Sarepta, RNA therapeutics, Duchenne muscular dystrophy, DMD, exon skipping, eteplirsen |
|
February 02, 2013 Sarepta Therapeutics |